An observational study in Aphasia, Development, Human and Neuropathology, sponsored by Bartosz M. Radtke. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Bartosz M. Radtke · Observational
The goal of this observational study is to investigate cognitive functioning profiles in adults with neurologically recognized aphasic syndromes and general population.
The study group consist of minimal 600 adults (over 18 y.o.) who will be examined by qualified diagnosticians. Participants will be evaluated with tasks related to the studied variables: memory, learning and language. Furthermore informations regarding past and present health condition will be collected from participants.
The main questions it aims to answer are:
Researchers will compare the following groups of adults:
338 studies on the registry are indexed under Aphasia; 95 are open to participants now.
This study's planned enrollment of 600 is above the median of 77 across 36 observational studies indexed under Aphasia.
Browse Aphasia studies →Bartosz M. Radtke is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Polish adults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion criteria for general population/control group:
Inclusion criteria for neurologically recognized aphasic syndromes
Inclusion criteria for seniors:
Exclusion criteria for general population/control group:
Exclusion criteria for neurologically recognized aphasic syndromes
Exclusion criteria for seniors
Polish adults (age 18 to 60 y.o).
Diagnostic Test: Psychological assessment
Polish adults (age 18 to 60 y.o) with neurologically recognized aphasic syndromes.
Diagnostic Test: Psychological assessment
Polish adults (over 60 y.o.)
Diagnostic Test: Psychological assessment
Psychological assessment of memory, learning and language
Memory and learning
Test of Memory and Learning (second edition). A standardized test measuring memory functioning and learning abilities. The test includes four basic factors (Verbal Memory, Nonverbal Memory, Complex Memory, and Delayed Recall) and five supplementary factors (Attention/Concentration, Sequential Memory, Free Recall, Associative Recall and Learning). The raw scores obtained in each tested subscale are converted into scores scaled based on age norms, ranging from 1 to 20, where a higher score means better functioning of the examined area, and a lower result means poorer functioning.
Time frame: July 3, 2023 until June 30, 2026
Language
Boston Diagnostic Aphasia Examination-Third Edition. A spectrum of tools that helps to identify and distinguish among disorders of language function and neurologically recognized aphasic syndromes. The test have five functional subsections: 1) Conversational and Expository Speech, 2) Auditory Comprehension, 3) Oral Expression, 4) Reading and 5) Writing. The raw scores obtained in each tested subscale are converted into a percentile scale, ranging from 1 to 100, where a higher score means better functioning of the examined area, and a lower result means poorer functioning.
Time frame: July 3, 2023 until June 30, 2026
Socio-demographic data
Author's survey of socio-demographic data, including: gender, month and year of birth, region of residence
Time frame: July 3, 2023 until June 30, 2026
General mental state
Mini-Mental State Examination. A clinical scale used to examine disorders in a patient's cognitive functioning. The questionnaire consists a series of questions allowing the assessment of the following functions: 1) orientation in time and place, 2) attention/concentration, 3) short-term memory (recall), 4) language skills, 5) visual-spatial abilities, 6) ability to understand and follow the instructions. The maximum score that can be obtained on the test is 30 points. 27-30 is a correct result; 24-26 is a cognitive impairment without dementia; 19-23 mean mild dementia; 11-18 is a moderate degree dementia and 0-10 mean profound dementia.
Time frame: July 3, 2023 until June 30, 2026
Health related data
Author's survey of health related data, including: hearing, eyesight, hypertension, atherosclerosis, previous heart attack, diabetes, endocrine diseases, respiratory system diseases, musculoskeletal system diseases, nervous system diseases, kidney diseases, sleep disorders, hospitalizations, procedures under general anesthesia, cancer, medications.
Time frame: July 3, 2023 until June 30, 2026
Education data
Author's survey of education, including: years of education, level of education, occupation, level of education of the participant's parents.
Time frame: July 3, 2023 until June 30, 2026
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bartosz M. Radtke